Convalescent plasma therapy in patients with COVID-19

Basit Öğe Kaydı
dc.authorid0000-0002-3285-417X
dc.authorid0000-0001-9962-8882
dc.authorid0000-0003-3312-8476
dc.authorid0000-0003-1864-0316
dc.authorscopusid57189243089
dc.authorscopusid37115534400
dc.authorscopusid55274431700
dc.authorscopusid56370690600
dc.authorscopusid24821384000
dc.authorscopusid55672209100
dc.authorscopusid14022986200
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.contributor.authorYigenoğlu, Tuğçe Nur
dc.contributor.authorHacıbekiroğlu, Tuba
dc.contributor.authorBerber, İlhami
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorBaştürk, Abdulkadir
dc.contributor.authorNamdaroğlu, Sinem
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:39:58Z
dc.date.available2022-05-11T14:39:58Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThere are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.
dc.identifier.doi10.1002/jca.21806
dc.identifier.endpage373
dc.identifier.issn0733-2459
dc.identifier.issn1098-1101
dc.identifier.issue4en_US
dc.identifier.pmid32643200
dc.identifier.scopus2-s2.0-85087740794
dc.identifier.scopusqualityQ2
dc.identifier.startpage367
dc.identifier.urihttps://doi.org/10.1002/jca.21806
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8817
dc.identifier.volume35
dc.identifier.wosWOS:000547463700001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Clinical Apheresis
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectconvalescent plasma
dc.subjectCOVID-19
dc.subjectSARS CoV-2
dc.subjectAntibody
dc.subjectInfection
dc.subjectImmunity
dc.subjectDisease
dc.titleConvalescent plasma therapy in patients with COVID-19
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8817.pdf
Boyut:
877.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu